PTPN11 and plasma cell myeloma: To determine whether combined exposure to bortezomib and SHP2 inhibitors would have a synergistic effect on the survival of myeloma cells, RPMI-8226 and NCI-H929 cells were cultured with different doses of bortezomib or SHP2 inhibitors alone or in combination for 48 h and the CCK-8 assay was measured.